The Effects of SGLTi on Diabetic Cardiomyopathy

Sponsor
The University of Hong Kong
Study ID
NCT04200586
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.

Study Details

Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is considered as a cardiac muscle disorder secondary to diabetes mellitus (DM). Certain studies show the clinical benefit of SGLT-s inhibitors on reducing cardiovascular outcomes amongst patients with type II DM that go beyond the correction of hyperglycemic perse. Thus an observational imaging study is proposed to identify mechanistic insights of the drug group over cardiovascular events.

Key Dates

Start date
Apr 9, 2020
Status verified
Aug 2021
Primary completion
Mar 4, 2021
Completion
Sep 30, 2021

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
    Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground

Primary Outcome Measure

Change in myocardial perfusion reserve index [ Time Frame: 8-12 weeks ]

Related Studies